Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

SkinPen

Also known as: skin pen, skinpen precision, skinpen, skinpen precision elite

SkinPen is a branded powered microneedling system made by Bellus Medical LLC, trading as Crown Aesthetics. Its 2018 US De Novo created the Class II microneedling-device type; the manufacturer describes broader CE-marked UK and EU uses, but no public certificate confirming those claims was located.

Evidence status

Manufacturer-supported

SkinPen has clinical evidence for selected indications, including FDA-reviewed acne-scar data, an uncontrolled neck-wrinkle study and a blinded, site-matched stretch-mark comparison, but the literature is small and largely uncontrolled. Every located device study was manufacturer-funded and/or manufacturer-authored, with no independent head-to-head pen trial; the FDA De Novo effectiveness analysis used only 20 marketed-device subjects and discarded one endpoint. UK/EU intended-use claims are broader than the public clinical dataset, and the notified-body dossier is not public.

What SkinPen is, and the systems available#

SkinPen is a motorised pen whose disposable cartridge mechanically punctures skin. The original SkinPen Precision System received US De Novo authorisation in 2018, creating 21 CFR 878.4430, the Class II category “microneedling device for aesthetic use”, with product code QAI. It was the first authorisation in that category; by July 2026, QAI contained the original De Novo and 25 later 510(k) clearances, so SkinPen is now one of several authorised devices of the type.[1, 5]

The current US generation is SkinPen Precision Elite. Its 2024 clearance names the applicant as Bellus Medical LLC, doing business as Crown Aesthetics. The changes concerned the interface, cartridge connection and an NFC cartridge-verification chip; FDA records that no clinical testing was conducted for that submission. Its clinical claims therefore inherit substantial equivalence to the earlier system rather than a new patient dataset.[4]

The corporate record is a rebranding and parent-company chain, not evidence that the device itself repeatedly changed owner. Bellus Medical was described as Crown Aesthetics by 2021 and remained the named legal applicant in 2024. A 2026 SkinPen paper described Crown Aesthetics as part of Revance.[4, 8, 10]

This entry covers the brand, its regulatory record and product-specific evidence. The technique, general indications, treatment planning and aftercare belong to microneedling.

Use of SkinPen in aesthetic practice#

US authorisation and UK market access are separate questions. In the United States, SkinPen is an “Rx only” prescription device. That legend reflects 21 CFR 801.109 and does not create a British prescription requirement. The 2018 US indication was improvement in the appearance of facial acne scars in adults aged 22 years or older; a 2021 clearance added neck wrinkles in Fitzpatrick skin types II–IV while retaining acne scars for all Fitzpatrick types.[1, 2][1, 2, 14][3]

The manufacturer describes SkinPen in the UK and EU as a CE-marked Class IIa device with a much broader intended use: facial acne scars; fine lines and wrinkles of the face and neck; pigmentation including melasma and vitiligo; and, from 2022, surgical scars, stretch marks and enlarged pores across the body. These are manufacturer statements in company press releases. No public CE certificate, notified-body record or supporting dossier was located.[10, 11]

For Great Britain, FDA status has no legal force. A medical device must be UKCA marked or qualify for transitional CE acceptance, registered with the MHRA and, where the manufacturer is outside the UK, linked to a UK Responsible Person. Legacy MDD or AIMDD certificates are accepted only until the sooner of certificate expiry or 30 June 2028; EU MDR certificates may be accepted until 30 June 2030. Publicly available records did not establish SkinPen's precise certificate route, MHRA registration or UK Responsible Person, so those records should be obtained from the supplier rather than inferred from the US marketing page.[14][12][no source found]

English licensing tiers remain proposals. The 2023 consultation placed microneedling in a proposed green tier, and the August 2025 response retained the proposal while announcing further work; no English scheme is in force. Scotland's 2026 Act expressly names microneedling, but the relevant provisions were not in force at Royal Assent and commencement is staged. The four Welsh statutory special procedures do not include microneedling. These jurisdictional facts concern practice regulation, not the product's clinical effectiveness.[15, 16][17][18]

Contraindications and cautions#

The contraindications, anatomical limits and preparation requirements in the instructions for the exact SkinPen generation and cartridge govern. A general brand page cannot safely replace that document.

Three evidence boundaries deserve particular attention. First, FDA's device classification excludes systems intended for transdermal delivery of cosmetics, drugs or biologics, and SkinPen's own limitations repeat that it is not intended for such delivery. Combining it with a serum, exosome preparation or booster for the purpose of driving that material through the skin is outside the stated US device purpose.[1, 2]

Second, the 2018 acne-scar labelling states that safety and effectiveness beyond 1.5 mm had not been evaluated and warns about superficial nerves and vessels. That statement belongs to the 2018 dataset rather than a universal permanent ceiling: the later neck study used the device at up to 2.5 mm. Selection must therefore follow the current instructions for the exact indication and anatomical site, not a depth number detached from its document.[2][3, 6]

Third, population limits travel with the indication. The neck clearance is restricted to Fitzpatrick II–IV and its supporting cohort contained no participants at V or VI. The acne-scar trial covered II–VI and included 11 of 41 participants at V–VI. Extrapolation from one indication to the other is not established by those data.[2, 3]

Clinical uses and the evidence behind them#

Facial acne scars

The pivotal study was single-centre, uncontrolled and unrandomised. Sixty-five participants enrolled and 41 completed, but only 20 completers received the marketed SkinPen Precision; the remaining 21 used a prototype with a different needle count and motor speed. Effectiveness was analysed in the 20 marketed-device users. The original Goodman and Baron measure was abandoned because it was not validated for the outcome, and another listed endpoint was discarded because the image selection made it clinically meaningless.[2][2]

At six months, the blinded mean acne-scar grade moved from 2.80 to 2.35, a change of −0.45 on a five-point scale. Eleven of 20 improved and nine showed no change; FDA published no significance test and described the change as clinically meaningful. Patient reports were more favourable: 18 of 20 reported some improvement, none reported worsening, 17 were satisfied and 18 would recommend treatment. FDA considered both benefit and risk and concluded that probable benefits outweighed probable risks.[2][2]

The two views should remain together. The photographs show a modest average effect in a small uncontrolled sample; the patients reported a more favourable experience. Neither supports a promise of a large or universal result.

Neck wrinkles

The 2021 dataset enrolled 35 people and analysed 32, mostly White women, aged 44–65 and Fitzpatrick II–IV. The blinded Lemperle score fell from 3.31 to 2.45, with 16 of 32 gaining at least one grade. On the clinician global assessment, however, 57% were rated “no change” at three months. The peer-reviewed paper says raters were deliberately unblinded to pretreatment images for that global scale, while FDA's summary describes them as blinded.[3, 6]

Patient satisfaction also declined between one and three months: noticing improvement fell from 93.8% to 71.9%, favourable satisfaction from 87.5% to 75.0%, and willingness to recommend from 80.6% to 65.6%. The result supports a possible short-term improvement in the studied population, with durability beyond three months unresolved.[3, 6]

Facial lines and stretch marks

A company-authored paper using the same neck cohort reported statistically significant changes across several facial wrinkle regions. It was uncontrolled, and the study's limitations include its small and demographically narrow sample.[7]

The most controlled SkinPen-associated study concerned striae. Twenty-nine participants contributed 34 treated regions with untreated site-matched regions on the opposite side; graders were blinded to visit and treatment status. Manchester Scar Scale improvement at six months was 48.89% for striae rubrae and 41.61% for striae albae. The study pooled SkinPen Precision with MicroPen EVO, so the effect cannot be assigned to SkinPen alone. It was manufacturer-funded and manufacturer-authored.[8]

Other advertised indications

The manufacturer publishes CE intended-use claims for enlarged pores, surgical scars, melasma and vitiligo, but no SkinPen clinical dataset for melasma or vitiligo and no public notified-body evidence review was located. The absence of a public trial is not proof that no technical dossier exists; it limits what can be represented as published clinical evidence.[10, 11]

The clinical papers themselves are indexed under generic descriptions such as “a microneedling device”, not the SkinPen trade name; the only indexed title or abstract containing “SkinPen” was an unrelated handheld bioprinter study in rats.[6, 7, 8, 13]

In both registration studies the treatments were delivered by a trained aesthetician — in the neck study explicitly 'under direct supervision of a licensed Physician' — so the device's own evidence base was generated by non-medical operators working inside a supervised clinical trial.[2, 3]

Selecting a SkinPen system#

Selection starts with identity and documentation: the Precision and Precision Elite are separate clearances, and the Elite has no clinical study of its own. Evidence cited for it comes from the earlier Precision generation or from pooled studies.[4, 5, 8]

The supplier record should establish the exact device, current instructions for use, declaration of conformity, certificate and expiry, notified body, MHRA registration and UK Responsible Person. A UK-facing page that cites DEN160029, K202243 and “Rx only” does not establish British market compliance.[12][14]

Evidence should then be matched to the proposed claim. The adult acne-scar indication has the public De Novo dataset; neck wrinkles have a separate, Fitzpatrick-limited dataset; the striae study pooled devices; and several broader manufacturer indications have no published SkinPen study. No head-to-head trial establishes that SkinPen produces a better clinical outcome than another pen. Its regulatory paper trail, controlled cartridges and training may still be product-selection factors, but they are not evidence of comparative superiority.

Treatment settings, cartridge use, preparation and post-treatment care are governed by the current manufacturer instructions and training for that model. Skinipedia does not substitute a generic protocol.

Adverse effects and their management#

Expected short-lived responses

In the pooled pivotal safety dataset, redness, itching, peeling, discomfort or tenderness occurred in 13 of 41 participants and lasted one to three days; dryness occurred in five and lasted one to six days; burning in four for one to three days; roughness in three for one to two days; and tightness in two for one to two days.[2]

In the neck study, reported responses included dryness, peeling, redness, burning, itching and tenderness, generally over one to seven days. The FDA summary printed peeling as eight of 32 and “22%”, although eight of 32 is 25%. No device-related adverse event was observed in that study at the three-month visit.[3]

Interim worsening and recorded events

Blinded graders scored 20% of the pivotal cohort worse than baseline at day 30, day 60 and one month, although no participant remained worse at six months and no patient rated their own scars as worse. FDA recorded five non-serious adverse events across two of the 65 enrolled participants; one marketed-device user experienced erythema, oedema, pruritus and skin striae, with the striae judged possibly related and resolving.[2]

Serious or persistent complications

FDA's device-type risk table includes damage to nerves and blood vessels, scarring, hyperpigmentation or hypopigmentation, infection, cross-contamination and adverse tissue reaction. Persistent, severe or unexpected findings require cessation of treatment, clinical assessment and device-incident handling under the clinic's current policies and manufacturer instructions.[1, 2]

Referral and scope boundaries#

Microneedling does not convert a medical diagnosis into an aesthetic indication. Active or unexplained pigment change, suspected vitiligo, infected or poorly healing skin, neurological symptoms, significant bleeding, progressive scarring, or a reaction outside the expected short-lived pattern requires appropriate medical assessment. The broader manufacturer marketing language does not establish that an aesthetic practitioner should treat a disease.[1, 10, 11]

Where a complication may involve the device or cartridge, the supplier and manufacturer reporting route is used alongside clinical referral and any applicable MHRA incident process. The practitioner's role is to record the exact system, cartridge, settings, site, timing and observed course; diagnosis and medical treatment remain with an appropriately qualified clinician.

Mechanism of action#

SkinPen's needles mechanically puncture and injure skin tissue; it does not deliver radiofrequency or another energy modality. FDA defines the whole device type in those terms and separates it from devices intended to deliver topical products through skin.[1]

The tissue response and general evidence for collagen induction belong to the microneedling and wound-healing cascade entries. A mechanism shared by a device class does not demonstrate that one brand outperforms another.

Commonly misstated claims#

“SkinPen is FDA approved”

SkinPen received a De Novo classification in 2018 and subsequent 510(k) clearances. Those are not premarket approval, and none has legal force in Britain.[1, 3, 4, 5, 12]

Supported statement: SkinPen was the first US-authorised Class II microneedling device and later received indication and generation clearances.

“FDA clearance proves rejuvenation, pigmentation and pore claims”

The US record covers adult facial acne scars and neck wrinkles in Fitzpatrick II–IV. The broader pigmentation, pore and body-scar uses are manufacturer-described CE indications, not FDA-authorised indications, and their public evidence varies.[1, 3][10, 11, 2]

Supported statement: evidence and regulatory wording must be attached to the named indication and jurisdiction.

“SkinPen is backed by more than 90 clinical studies”

The manufacturer's wording is “more than 90 validation studies”, with substantiation described as regulatory filings, company clinical studies, internal research and consumer surveys. FDA special controls include engineering, software, sterility and bench validation as well as clinical evidence.[1, 2, 14]

Supported statement: SkinPen has an extensive validation and regulatory file; the located clinical literature is small and manufacturer-connected.

“The Elite is the clinically proven latest generation”

The 2024 Elite 510(k) says no clinical testing was conducted for that submission.[4, 5]

Supported statement: the Elite was cleared through substantial equivalence, supported by bench, software, biocompatibility and usability work, while patient evidence comes from earlier systems.

Areas of remaining uncertainty#

  • The precise CE route, certificate expiry, MHRA registration and UK Responsible Person remain publicly unverified; this means clinics need the current documents from the supplier before relying on UK market claims.
  • No published evidence explains what supported the broader CE indications for vitiligo, melasma, pores and several body indications; this limits the claims that can be represented as published clinical outcomes.
  • FDA and the peer-reviewed neck paper disagree on whether the global-scale graders were blinded; this reduces confidence in interpreting that secondary endpoint.
  • Acne-scar follow-up ends at six months and neck follow-up at three months; this prevents a durable-effect claim.
  • No independent or head-to-head SkinPen trial was located; this prevents an evidence-based claim of superiority over another powered pen.

Frequently asked questions#

Is SkinPen FDA approved?

No. It received a De Novo classification and later 510(k) clearances. “FDA approved” is the wrong regulatory description.[1, 3, 4, 5]

Does FDA clearance permit use in the UK?

No. GB market access depends on the applicable UKCA or transitional CE route, MHRA registration and a UK Responsible Person where required.[12]

Can SkinPen be used to infuse serums or exosomes?

Not within the stated US device purpose. The classification expressly excludes transdermal delivery of cosmetics, drugs and biologics. The current instructions for the UK-supplied system govern.[1, 2]

Is the Precision Elite supported by its own trial?

No. FDA states that no clinical testing was conducted for its 2024 submission; it relies on substantial equivalence.[4]

Is SkinPen proven superior to other pens?

No head-to-head trial was located. Its clinical literature supports selected uses of the studied systems but does not establish comparative superiority.

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. US Food and Drug Administration, Center for Devices and Radiological Health. De Novo classification order, DEN160029, SkinPen Precision System (Bellus Medical, LLC, Addison, Texas). Issued 1 March 2018.Tier 1Supports: The classification order granted to Bellus Medical, LLC, dated 1 March 2018 (De Novo dated 1 July 2016, received 5 July 2016). Indications for use verbatim: 'SkinPen® Precision System is a microneedling device and accessories intended to be used as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older.' Creates regulation 21 CFR 878.4430, regulation name 'Microneedling device for aesthetic use', Class II, product code QAI. Generic type defined verbatim: 'A microneedling device for aesthetic use is a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use. This classification does not include devices intended for transdermal delivery of topical products such as cosmetics, drugs, or biologics.' States: 'In addition, this is a prescription device and must comply with 21 CFR 801.109.' Imposes ten special controls (needle specification; non-clinical performance including accuracy of penetration depth and puncture rate and identification of maximum safe needle penetration depth; sterility; shelf life; electrical safety and EMC; software V&V; biocompatibility; reprocessing validation; device labelling; patient labelling). The risk table lists 'Damage to underlying tissue including nerves and blood vessels, scarring, and hyper/hypopigmentation due to: Exceeding safe penetration depth / Mechanical failure / Software malfunction', alongside adverse tissue reaction, cross-contamination and infection, and electrical shock or EMI. Scope limit: a US classification order only; it makes no finding about markets outside the United States. Verified against the PDF in full, 4 pages, 1 August 2026.
  2. US Food and Drug Administration. De Novo Classification Request for SkinPen Precision System — Decision Summary, DEN160029. 21 pages.Tier 1Supports: The full FDA review, verified page by page. LIMITATIONS section states verbatim: 'The sale, distribution, and use of the SkinPen Precision System is restricted to prescription use in accordance with 21 CFR 801.109'; 'This product is not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics'; and 'Safety and effectiveness for needle depth settings greater than 1.5 mm has not been evaluated.' Device offers '11 depth settings from 0 mm to 2.5 mm in 0.25 mm increments', 14 needles, motor 7000 RPM (6300-7700). Labelling adds: 'it is not recommended to treat at needle depths greater than 1.5mm' because of fine structures under the skin, naming the supraorbital nerve and the temporal, buccal and marginal mandibular branches of the facial nerve; recommended procedure depths are forehead 0.25-1.0 mm, nose 0.25-0.75 mm, around (not within) the orbital rim 0.25-0.5 mm, facial acne scars up to 1.5 mm. PIVOTAL STUDY: single centre; treatments day 1, 30, 60 with follow-up at 1 month and 6 months; treatments delivered by 'a trained aesthetician (skin care specialist)'; operators instructed to start at the lowest depth and increase until erythema was observed, maximum 1.5 mm; no control arm. Accountability: 65 enrolled overall (33 in the SkinPen Precision group), 41 completed (20 in the SkinPen Precision group); 24 discontinued (13 from the SkinPen Precision group), of which 11 overall were sponsor-requested 'for not having severe acne scars based on the images reviewed'. The other 21 completers were treated with a prototype device differing in needle count and motor speed; effectiveness analysis used only the 20 SkinPen Precision subjects, safety pooled across 41. ENDPOINT CHANGES: the original primary measure (Goodman and Baron qualitative grading by the treating investigator) was abandoned mid-study because 'this scale has not been validated for this outcome measure'; the Clinician's Global Aesthetic Improvement Assessment — one of the two listed primary effectiveness endpoints — was discarded because best and worst images 'were not chosen based on timepoint and therefore this endpoint was not considered to be clinically meaningful.' RESULTS (Acne Scar Assessment Scale, 0-4, blinded photo grading by two board-certified dermatologists, N=20): baseline mean 2.80 (SD 0.52); day 30 2.78; day 60 2.70; 1 month 2.68; 6 months 2.35 (SD 0.69). Change from baseline: improved 30.0% / 35.0% / 40.0% / 55.0% and worsened 20.0% / 20.0% / 20.0% / 0.0% at day 30, day 60, 1 month and 6 months respectively; mean change at 6 months -0.45 (-16.1%). At 6 months 7/20 (35%) achieved a full 1-grade reduction, 4 (20%) improved by less than 1 grade, and 9 (45%) showed no change. No p-value or significance test is reported for the primary endpoint; FDA simply states the improvements 'were considered to be clinically meaningful.' PATIENT-REPORTED RESULTS (which are markedly more positive than the photo grading and must be reported alongside it): on the Self-assessed Scar Improvement Scale 18/20 (90%) reported some improvement at 6 months and no subject reported exacerbation at either post-treatment timepoint; on the Subject Global Aesthetic Improvement Scale 18/20 (90%) reported improved or better at 6 months and no subject reported 'worse'; on the satisfaction questionnaire 18/20 (90%) noticed improvement, 17/20 (85%) were satisfied and 18/20 (90%) would recommend the treatment. 11/41 subjects were Fitzpatrick V-VI (the study enrolled FST II-VI; FST I was not assessed). SAFETY: the benefit-risk section records two subjects (2/65, 3.1%) with a total of five non-serious adverse events — one subject in the prototype group with an arthropod bite (moderate, unlikely related), and one subject in the SkinPen Precision group with erythema, oedema and pruritus of the face (mild, unlikely related) plus skin striae on the forehead and both sides of the face (mild, possibly related, attributed to sun exposure against instructions, resolved). FDA gives that second subject inconsistent denominators — 1/41 (2.4%) in the safety section and 1/41 (1.5%) in the benefit-risk section, the latter figure evidently being 1/65. There were no serious AEs and no reports of nerve or tissue damage, and no adverse events persisted at 6 months. Common treatment responses: redness/itching/peeling/discomfort/tenderness 13/41 (31%) lasting 1-3 days, dryness 5/41 (12%) lasting 1-6 days, burning 4/41 (9%) lasting 1-3 days, rough skin 3/41 (7%) lasting 1-2 days, tightness 2/41 (4%) lasting 1-2 days. FDA'S OWN CONCLUSION, which the sceptical reading must not omit: 'The probable benefits outweigh the probable risks for the SkinPen Precision System', and FDA notes the device 'has a lower risk profile than some of the alternative treatments' (lasers, peels) which 'are not typically performed on higher Fitzpatrick skin types due to the risks of pigment change'. Scope limits: single centre, no control, no randomisation, effectiveness N=20, 6-month maximum follow-up, facial acne scars only.
  3. US Food and Drug Administration. 510(k) Summary and clearance letter, K202243, SkinPen Precision System (Crown Aesthetics). Decision 2 April 2021.Tier 1Supports: Traditional 510(k) by Crown Aesthetics, Dallas TX; predicate K180778 (Exceed Microneedling Device), reference device DEN160029. Expanded indication verbatim: 'The SkinPen® Precision system is a microneedling device and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II - IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older.' Prescription use. Records 'Max. Needle Length used in the clinical study: 2.5 mm' for the subject device (against 1.5 mm for the predicate). NECK STUDY: single centre, 35 subjects enrolled (2 male, 33 female), 32 per-protocol, mean age 56.3 (SD 5.0), range 44-65; Fitzpatrick II 24 (75%), III 4 (12.5%), IV 4 (12.5%); 87.5% White/Caucasian. Four treatments (day 1, 30, 60, 90) at depths up to 2.5 mm, delivered 'Under direct supervision of a licensed Physician... by a trained aesthetician (skin care specialist)'. No control arm. Primary endpoint G. Lemperle Wrinkle Scale (0-5) by two blinded graders: neck mean 3.31 (SD 0.74) at day 1 falling to 2.45 (SD 0.93) at 3 months post-treatment; 16/32 (50%) achieved at least a 1-grade improvement. Secondary CGAIS at 3 months: 11.5% 'much improved', 31.5% 'improved', 57% 'no change'. NOTE A DISCREPANCY WORTH FLAGGING: this FDA summary describes the CGAIS as 'graded by two blinded graders', whereas the peer-reviewed publication of the same dataset (source 6) states the raters were deliberately unblinded to pre-treatment images for the CGAIS. Subject GAIS: 22/32 (68.8%) reported some improvement, 10 (31.3%) no change. Patient satisfaction FELL between timepoints and both sets of figures should be quoted: noticed improvement 93.8% at 1 month but 71.9% at 3 months; favourable satisfaction 87.5% at 1 month but 75.0% at 3 months; would recommend 80.6% at 1 month but 65.6% at 3 months. Safety: 'At the 3-month post-treatment visit, no adverse events were seen' and 'No adverse events related to the SkinPen Precision treatment were observed on the face and neck during the study'; common responses dryness 7/32 (22%), peeling 8/32 (printed as 22% by FDA; 8/32 is 25%), redness 2/32 (6%), burning 2/32 (6%), itching 1/32 (3%), tenderness 1/32 (3%), lasting 1-3 days for most, with tenderness and peeling/flaking recorded as lasting up to 1-7 days. Scope limits: neck indication restricted to Fitzpatrick II-IV; the cohort contained no Fitzpatrick V-VI subjects; 3-month follow-up only; uncontrolled.
  4. US Food and Drug Administration. 510(k) Summary and clearance letter, K241400, SkinPen Precision Elite System (Bellus Medical LLC, dba Crown Aesthetics). Decision 29 August 2024.Tier 1Supports: Clearance for the current-generation device, the SkinPen Precision Elite System, predicate K220506 (SkinPen Precision System). The 510(k) Summary names the submitter and owner as 'Bellus Medical LLC, dba Crown Aesthetics', Dallas, Texas — useful evidence that the original De Novo applicant entity persists and merely trades under the Crown Aesthetics name. Indications identical to K202243: neck wrinkles Fitzpatrick II-IV plus facial acne scars all Fitzpatrick types, adults 22+. Needle protrusion 0-2.5 mm, frequency 105-128.3 Hz and puncture rate 1470-1797 punctures/sec, all 'Same' as predicate. Section 12 states verbatim: 'No Clinical testing was conducted as part of this submission.' Changes are 'to the user interface, cartridge connection points, and the addition of an NFC chip for cartridge verification', supported by software verification and validation, IEC standards (60601-1, 60601-1-2, 62304, 60601-1-6), ISO 10993-1 biocompatibility, ISO 11135 sterilisation and usability testing, plus reciprocating-rate and puncture-depth bench testing. FDA records the manufacturer's position that these changes 'do not impact the device effectiveness, and safety is increased with the use of the NFC chip'. Scope limit: substantial-equivalence clearance only — the Elite generation carries no clinical dataset of its own.
  5. US Food and Drug Administration, openFDA device clearance and classification databases: records for device name 'SkinPen' and product code QAI. Data last updated 20 July 2026.Tier 1Supports: Four SkinPen authorisations exist, establishing the chronology: DEN160029 SkinPen Precision System, Bellus Medical, LLC, decision 1 March 2018 (Direct De Novo); K202243 SkinPen Precision System, Crown Aesthetics, decision 2 April 2021 (traditional); K220506 SkinPen Precision System, Crown Aesthetics, decision 7 March 2022 (special 510(k)); K241400 SkinPen Precision Elite System, Crown Aesthetics, decision 29 August 2024 (traditional). All are product code QAI, advisory committee General/Plastic Surgery, applicant city Dallas, Texas as recorded by openFDA (the 2018 order letter itself gives Addison, Texas). The classification record for QAI gives regulation 878.4430, class 2, device name 'Powered Microneedle Device', definition 'A powered microneedle device is a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use', not implant, not GMP-exempt, premarket notification required, review panel SU. The QAI product code now carries 26 authorisations in total — the original De Novo plus 25 subsequent 510(k) clearances — i.e. SkinPen is one of many devices in the type it created. Query re-run and verified 1 August 2026. Scope limit: a US administrative database; it records no CE, UKCA or MHRA status.
  6. Alqam M, Wamsley CE, Hitchcock T, Jones BC, Akgul Y, Kenkel JM. Efficacy and Tolerability of a Microneedling Device for Treating Wrinkles on the Neck. Aesthetic Surgery Journal. 2022;42(10):1154-1160. doi:10.1093/asj/sjac085. PMID 35397167, PMCID PMC9472661.Tier 3Supports: The peer-reviewed publication of the neck dataset behind K202243 (ClinicalTrials.gov NCT03803059). Citation verified against PubMed: authors, journal, 2022;42(10):1154-1160, DOI and PMID all correct. Full text confirms the device is the SkinPen Precision System: 'The 14 solid (0.25-mm) needles operate at a speed of 6300 to 7700 rpm with a maximum cartridge needle extension <2.5 mm.' N=35 enrolled, 32 completed; four monthly procedures at depths up to 2.5 mm. Blinding, verbatim: 'Two trained raters assessed blinded randomized images of subjects prior to treatment (Day 1) and 90 days posttreatment. After completing wrinkle assessment, the 2 raters were unblinded to pretreatment images for the Clinician's Global Aesthetic Improvement Scale (CGAIS).' Neck wrinkle improvement p<0.001; both GAIS scales p<0.001 at 90 days; 73.3% of subjects reported some improvement at 30 days and 68.8% at 90 days; satisfaction reported as 93.8% improvement, 87.5% satisfied, 80.6% would recommend. NOTE: those three satisfaction figures match the 1-MONTH column of the FDA's table for the same trial; the FDA summary records lower values at the 3-month endpoint (71.9%, 75.0%, 65.6%), so the paper's headline satisfaction numbers are the earlier and more flattering ones. Authors' own limitations, verbatim: 'Limitations to this study include a limited population size, lack of a longer follow-up period, and a bias for White, female subjects due to the difficulty finding higher Fitzpartrick skin types meeting inclusion criteria.' Further scope limits: uncontrolled, single centre, 90-day follow-up, and the clinician global scale was assessed unblinded.Funding / interest: Manufacturer-funded and manufacturer-authored. Disclosure verbatim: 'Drs Alqam, Hitchcock, and Jones are employees of Crown Laboratories (Dallas, TX), which is the manufacturer and distributor of the microneedling device, and provided sponsor-supported funding for this study. Drs Akgul, Kenkel, and Miss Wamsley report sponsor-supported funding from Venus Concept (Toronto, Ontario, Canada) for research studies outside of this submitted work.' Funding statement verbatim: 'All funding for this study was paid for by Crown Laboratories (Dallas, TX).' The accompanying invited commentary (Fernandes D, Aesthet Surg J 2022;42(10):1161-1162, PMID 35640251 — citation verified) carries its own commercial disclosure, verbatim: 'Professor Fernandes is a shareholder for Vivida SA (Cape Town, South Africa) and is a scientific director for Environ Skin Care (Cape Town, South Africa).'
  7. Alqam M, Wamsley CE, Hitchcock TM, Jones BC, Akgul Y, Kenkel JM. Efficacy and tolerability of a microneedling device for treating wrinkles on the face. Journal of Cosmetic Dermatology. 2023;22(1):206-213. doi:10.1111/jocd.14985. PMID 35403786, PMCID PMC10084046.Tier 3Supports: The face-wrinkle report from the same cohort and trial as source 6 (N=35 enrolled, 32 completed, mean age 56.3 (SD 5.0), NCT03803059); citation verified against PubMed; full text confirms the SkinPen Precision System. Four monthly procedures by a trained aesthetician per manufacturer instructions. Blinding is described identically to source 6: raters assessed blinded randomised images, then 'were unblinded to pre-treatment images for the Clinician's Global Aesthetic Improvement Scale (CGAIS)'. Face wrinkle assessment improved significantly (p<0.001); SGAIS improved at 30 and 90 days (each p<0.001); CGAIS improved at 90 days (p<0.001). Region-level proportions improved at 90 days, which a sceptical reading should not omit: cheek fine lines 87.5%, marionette lines 75.0%, upper lip 75.0%, glabellar folds 71.9%, forehead fine lines 68.8%, nasolabial fold 59.4%, periorbital 56.3%. Concludes: 'Microneedling is a safe, viable, and minimally invasive option for treating wrinkles of the face.' Authors' limitations: 'Limited population size, and a bias for white, female subjects due to the difficulty finding higher Fitzpatrick skin types meeting inclusion criteria.' Scope limits: uncontrolled, single centre, 90-day follow-up; this is the same 32 people as the neck paper, so the two publications are not independent replications. Note also that facial wrinkles are NOT an FDA-authorised SkinPen indication.Funding / interest: Manufacturer-funded and manufacturer-authored. Conflict statement verbatim: 'The authors Alqam, Hitchcock, and Jones are employees of Crown Laboratories, which is the Manufacturer and Distributor of the microneedling device, and sponsor of the study.' Akgul, Kenkel and Wamsley report sponsor-supported funding from Venus Concept. Funding: Crown Laboratories sponsored the clinical trial, conducted at UT Southwestern. Copyright is held by Crown Laboratories Inc. (© 2022 Crown Laboratories Inc., Journal of Cosmetic Dermatology published by Wiley Periodicals LLC).
  8. Marin S, Watterson A, Alqam ML, Jones BC, Hitchcock TM. A Comparative Study to Evaluate the Safety and Efficacy of Microneedling as a Stand-Alone Treatment for Striae Rubrae and Albae. Aesthetic Surgery Journal. 2026;46(5):530-542. doi:10.1093/asj/sjaf261. PMID 41401824, PMCID PMC13064658.Tier 3Supports: The most methodologically robust study in the SkinPen literature and the only one with a comparator. Citation verified against PubMed (Aesthet Surg J 2026;46(5):530-542, epub 7 April 2026). 29 subjects contributing 34 treatment regions — 15 striae rubrae and 19 striae albae; four monthly microneedling treatments; verbatim: 'Site-matched regions on opposite sides of the body were evaluated as untreated controls.' Follow-up at 3 and 6 months after the last treatment. Graders were blinded — verbatim: 'Graders, who were blinded to the visit and treatment status, compared each set of photos using a modified CGAIS-style scale.' Manchester Scar Scale improvement over baseline, verbatim: striae rubrae 'showed 43.89% and 48.89% MSS score improvements over baseline at 3 and 6 months, respectively, compared with 36.69% and 41.61% for striae albae' — i.e. early-stage stretch marks responded better. 'All reactions were transient, and no adverse events were reported.' Treatment depths 0.25-2.5 mm, increasing at successive visits. IMPORTANT SCOPE LIMIT for a brand entry: two devices were used, not one — 'Both microneedling devices (SkinPen Precision® and MicroPen EVO™; Crown Laboratories, Inc., Johnson City, TN) are classified as Class II surgical instruments under CFR 878.4430' — so results cannot be attributed to SkinPen alone. Authors' own limitations: sample size and length of follow-up (6 months), 89.7% female participants, and stretch-mark regions 'mainly limited to abdomen and hips' — body sites, not face.Funding / interest: Manufacturer-funded and manufacturer-authored. Disclosure verbatim: 'All authors were employed by Revance, Inc. (Nashville, TN; formerly Crown Laboratories, Inc., Johnson City, TN) during their involvement in this work, and the devices used in this study are products of Revance. The authors declare no other potential conflicts of interest with respect to the research, authorship, and publication of this article.' Funding statement: 'This study was funded by Revance, Inc. (Nashville, TN; formerly Crown Laboratories, Inc., Johnson City, TN).' This disclosure is also the only peer-reviewed attestation we located of the group's renaming to Revance, Inc.
  9. Crown Aesthetics (formerly Bellus Medical; a Crown Laboratories brand). Press release: 'SkinPen Precision Now Under Direct Management in the United Kingdom and Ireland.' 12 April 2021.Tier 4Supports: The clearest manufacturer statement of the claimed UK/EU regulatory basis and the UK-relevant intended use, which differs materially from the FDA indication. Verbatim: 'SkinPen's CE intended use includes treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appearance of fine lines and wrinkles on the face and neck. SkinPen also treats pigmentation conditions (Dyschromia) including Melasma, Vitiligo, and Solar Lentigines (sun/age spots).' And: 'SkinPen Precision is a Class IIa medical device that works by creating controlled micro-injuries to stimulate the body's natural wound-healing response'. Also states SkinPen was 'Launched in 2013 and backed by over 90 validation studies' and is 'clinically proven effective on all Fitzpatrick skin types'. Describes the company verbatim as 'Crown Aesthetics (formerly known as Bellus Medical)' — direct evidence that Crown Aesthetics is a renaming of the De Novo applicant, not a separate acquirer. Confirms Crown Aesthetics took direct control of UK and Ireland distribution on 12 April 2021, replacing a distributor arrangement, with customer service based in Ballyclare, Northern Ireland, and the UK/Ireland site given as skinpen.uk. Note the claims to treat melasma and vitiligo are not supported by any published SkinPen study we could find, and vitiligo is a disease claim.Funding / interest: Issued by the manufacturer and UK distributor of the device. Promotional material; no external verification of the CE intended-use wording, certificate number or notified body is provided.
  10. Crown Aesthetics. Press release: 'Award-Winning SkinPen Precision Announces New and Expanded Approved Indications in the EU and UK.' 6 October 2022.Tier 4Supports: Documents the claimed widening of the UK/EU intended use well beyond anything FDA authorised. Verbatim: the device 'has received three new approved indications in the EU and UK'; 'The certification confirms SkinPen Precision as a treatment which can help to improve the appearance of surgical scars, stretch marks, and enlarged pores on all areas of the body.'; 'The device is also approved for medical purposes to treat facial acne scars in adults aged 22 years or older and for aesthetic purposes to help improve the cosmetic appearance of fine lines, wrinkles, and pigmentation conditions (dyschromia).' Claims 'over two million SkinPen Precision treatments have already been performed worldwide'. Scope limits and honest caveats, confirmed on re-reading the release in full: it names no notified body, no certificate number, no EU MDR or MDD basis, and cites no clinical data for the three new indications; the word 'approved' describes a notified-body conformity assessment, not a regulator's evaluation of efficacy, and unlike the FDA route no public evidence summary is produced.Funding / interest: Issued by the manufacturer. Promotional announcement of its own certification; no independent corroboration located.
  11. Medicines and Healthcare products Regulatory Agency (MHRA). Guidance: Regulating medical devices in the UK. GOV.UK. Page last updated 20 February 2026.Tier 1Supports: The governing UK framework. Devices placed on the Great Britain market require a UKCA mark under the UK Medical Devices Regulations 2002, with transitional acceptance of CE marking. Verbatim: 'general medical devices compliant with the EU MDD or EU AIMDD can be placed on the Great Britain market up until the sooner of expiry of certificate or 30 June 2028'; 'general medical devices, including custom-made devices, compliant with the EU MDR... can be placed on the Great Britain market up until 30 June 2030'; 'IVDs compliant with the EU IVDD can be placed on the Great Britain market up until the sooner of expiry of certificate or 30 June 2030'. Registration, verbatim: 'All medical devices, including IVDs, custom-made devices and systems or procedure packs must be registered with the MHRA before being placed on the Great Britain market.' UK Responsible Person, verbatim: 'Manufacturers based outside the UK must appoint a UK responsible person' to carry out specified tasks, including registering the device with the MHRA, before it is placed on the Great Britain market. Scope limit: this is the device-marketing framework only. It regulates who may place the device on the market, not who may operate it on a patient — there is no MHRA licence for practitioners.
  12. NCBI PubMed records for the terms 'SkinPen', 'SkinPen'[tiab], 'SkinPen Precision' and 'Crown Aesthetics'; MHRA Public Access Registration Database. Accessed 1 August 2026.Tier 4Supports: Documents what is absent. A PubMed search for 'SkinPen' returns exactly ONE indexed record (PMID 37262337), and it is not this device: Zhou F et al., 'Portable Handheld "SkinPen" Loaded with Biomaterial Ink for In Situ Wound Healing', ACS Applied Materials & Interfaces 2023;15(23):27568-27585 — an unrelated handheld bioprinter depositing GelMA/Cu-bioactive-glass hydrogel, tested in diabetic rats. 'SkinPen'[tiab] returns the same single record; a search for 'SkinPen Precision' returns zero records. Both counts re-verified on 1 August 2026. The brand name therefore appears in no indexed title or abstract for the microneedling device; the manufacturer's own papers are indexed only as 'a microneedling device' or 'a microneedling pen', with the trade name appearing solely in the full text. Separately, the MHRA PARD at pard.mhra.gov.uk is a JavaScript single-page application: the site root and every candidate API path returned the application shell rather than data, so SkinPen's GB registration status could not be verified programmatically. This is an access failure, not evidence of absence of registration.
  13. skinpenuk.com — SkinPen Precision Elite, UK-facing brand website (Crown Aesthetics / Revance). Accessed 1 August 2026.Tier 4Supports: Shows what UK buyers are actually told. The UK-facing site's regulatory footnotes cite only United States authorisations: 'SkinPen Precision System is classified under De Novo DEN160029 as a Class II device' and 'SkinPen Precision System is cleared under 510(k) number K202243 for improving the appearance of wrinkles on the neck.' It reproduces the US indications (neck wrinkles Fitzpatrick II-IV; facial acne scars, all Fitzpatrick types, adults 22+) and the US legend 'Rx only' — a 21 CFR 801.109 prescription restriction that has no counterpart in UK law — and directs enquiries to enquiries@revance.com. It references 'more than 90 validation studies', and footnotes efficacy claims as 'Clinical data and summaries are derived from regulatory filings, Crown Aesthetics' clinical studies, internal research, and consumer surveys.' We found no UKCA mark, CE mark, notified body, MHRA registration number or UK Responsible Person stated anywhere on the page. Scope limit: a live marketing page that can change; the observation is dated to the access date above, and only the page itself was verified — related corporate sub-pages were not re-verified on this pass.Funding / interest: Manufacturer's own marketing website; every claim on it is commercially self-interested.
  14. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation document. Consultation open 2 September to 28 October 2023.Tier 1Supports: The consultation proposed green, amber and red licensing tiers and expressly included microneedling in the proposed green list. The document says the lists are indicative, not final or complete, and may change; it is a proposal rather than law.
  15. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. Published 7 August 2025.Tier 1Supports: The response restates the proposed tier lists, including microneedling in green, but does not finalise them in law. It announces further work and consultation; no licensing scheme was in force in England at the research date.
  16. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (2026 asp 13), schedule 1 and section 24(2).Tier 1Supports: Schedule 1 expressly names microneedling as a specified non-surgical procedure. The relevant paragraphs were not in force at Royal Assent and commencement is staged. Scotland only.
  17. Public Health (Wales) Act 2017 (anaw 2), section 57 'What is a special procedure?'. In force 29 November 2024 by S.I. 2024/1248.Tier 1Supports: Section 57 names exactly acupuncture, body piercing, electrolysis and tattooing as special procedures. Microneedling is not one of those four. Wales only.